Late-breaking ESMO presentation shows Libtayo (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy

In a prespecified analysis of patients with confirmed PD-L1 expression of ≥50%, Libtayo reduced risk of death by 43%